Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous Leukemia

Completed · Phase 2

Conditions studied: Leukemia

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have relapsed or refractory chronic myelogenous leukemia.

Key facts

Study ID

NCT00005618

Run by

Memorial Sloan Kettering Cancer Center

Starts

2000-02-01

Expected to finish

2004-03-01

Last updated by the study team

2013-06-21

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Memorial Sloan-Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.